15 in stock
NAD+ 500 mg is a research-grade form of nicotinamide adenine dinucleotide, an essential coenzyme at the centre of cellular energy production, redox balance, mitochondrial function, DNA-repair signalling and healthy-aging research.
Dinucleotide Coenzyme
NAD+ and NADH
Energy, Mitochondria and Repair
Strong Biology, Developing Human Evidence
NAD+ stands for nicotinamide adenine dinucleotide. It is found in every living cell and is required for hundreds of biochemical reactions. Although it is sometimes grouped with peptide products, NAD+ is technically a dinucleotide coenzyme made from nucleotide components rather than amino acids.
NAD+ works in partnership with its reduced form, NADH. Together, they transfer electrons during cellular metabolism. This redox cycle helps convert nutrients into usable energy through glycolysis, the citric-acid cycle and mitochondrial oxidative phosphorylation.
In addition, NAD+ acts as a required substrate for sirtuins, PARP enzymes and CD38-related pathways. Therefore, its research significance extends well beyond energy production into DNA repair, gene regulation, stress responses, immune signalling and cellular aging.
| Research Area | What the Evidence Shows | Evidence Context |
|---|---|---|
| Energy Metabolism | NAD+/NADH is indispensable for electron transfer, mitochondrial respiration and normal ATP-generating metabolism. | Foundational biochemistry supported across cellular and organism research. |
| Aging Biology | Reduced NAD+ availability has been observed with aging in multiple tissues and is linked to altered mitochondrial, sirtuin and DNA-repair activity. | Strong mechanistic and preclinical evidence; human outcome research remains active. |
| Direct NAD+ Administration | Human pilot research demonstrates rapid processing of administered NAD+ and measurable changes in circulating NAD+ metabolites. | Small pharmacokinetic and tolerability studies, not large efficacy trials. |
| NAD+ Augmentation | NR, NMN, nicotinamide and other strategies can raise NAD-related biomarkers in several human studies. | Biological activity is clear, while clinical benefits vary by compound, route and endpoint. |
NAD+ availability can change when synthesis slows or consumption rises. For example, the salvage pathway recycles nicotinamide back into NAD+, with NAMPT serving as an important rate-limiting enzyme. Meanwhile, sirtuins, PARPs and CD38 continually consume NAD+ as they carry out signalling and repair functions.
During aging and chronic metabolic stress, researchers have observed lower NAD+ levels in several tissues. Increased CD38 activity, reduced precursor availability, altered NAMPT expression and persistent DNA-repair demand may all contribute.
As a result, restoring or preserving NAD+ has produced encouraging findings in experimental models involving mitochondrial performance, metabolic flexibility, muscle function, neuronal stress and cellular resilience. Translating those findings into reliable human outcomes is now a major focus of longevity research.
A 2019 pilot study tracked NAD+ and its metabolites during a six-hour controlled infusion. During the first two hours, researchers did not observe an accumulation of NAD+ or its measured metabolites in plasma or urine. This pattern was consistent with rapid tissue uptake, metabolism or both. Later in the study, circulating NAD+ and several metabolites increased measurably.
More recently, a 2026 retrospective pilot compared NAD+ with nicotinamide riboside across four consecutive infusion days. Both groups showed no clinically significant changes in the measured liver or inflammation markers during the observation period. However, NAD+ generally required a longer administration time because participants reported more infusion-related discomfort.
Together, these studies provide positive evidence that direct NAD+ administration is biologically active and can be investigated in humans. Nevertheless, they primarily address metabolism, short-term laboratory markers and tolerability—not proven anti-aging, energy or disease-treatment outcomes.
| Research Compound | Pathway | Research Distinction |
|---|---|---|
| Direct NAD+ | Supplies the complete dinucleotide to the extracellular environment. | Rapidly processed into NAD-related metabolites; cellular entry mechanisms are still being clarified. |
| Nicotinamide Riboside | Converted through the salvage pathway into NMN and then NAD+. | Has several human studies showing increases in blood NAD-related biomarkers. |
| Nicotinamide Mononucleotide | Acts as a direct NAD+ precursor within the salvage pathway. | Human studies are expanding, particularly in aging and metabolic research. |
| Nicotinamide / Niacin | Enters established vitamin B3-dependent NAD+ synthesis pathways. | Long history of human use, but pharmacology and tolerability differ from direct NAD+. |
Direct NAD+ human research has most often used controlled intravenous administration because researchers can precisely track exposure, metabolites and short-term laboratory changes. However, those protocols were designed for specific studies and cannot be assumed to apply to other routes, formulations or research objectives.
In addition, NAD+ biology is highly compartmentalized. Concentrations in whole blood, plasma, muscle and individual cell compartments do not necessarily change together. Therefore, a measured increase in one sample type does not automatically prove increased NAD+ inside every tissue.
The molecular importance of NAD+ 500 mg is exceptionally well established. Energy transfer, mitochondrial respiration, PARP activity and sirtuin function all depend on adequate NAD+ biology.
Furthermore, human studies support the ability of several NAD+ strategies to alter circulating biomarkers. Direct NAD+ research has also documented active metabolism and preliminary tolerability. These are encouraging foundations for future clinical work.
Still, biomarker movement is not identical to a proven health benefit. A recent systematic review concluded that NAD+ augmentation shows clear biological activity, while clinical effectiveness for generalized anti-aging and wellness outcomes remains inconclusive. Route, formulation, tissue uptake and study population all matter.
NAD+ 500 mg is supplied as a research-grade coenzyme for controlled laboratory investigation. Its central role in energy metabolism, mitochondrial biology and enzyme signalling makes it a valuable tool for modern cellular and longevity research.
Research use only. Product information summarizes published scientific findings and does not constitute medical advice, an administration protocol or a guarantee of results.
